

# Immunisation for adults post-haematopoietic stem cell transplantation(HSCT)

These recommendations are for adults who have received either an autologous or allogeneic graft. For children aged under 18 years, please refer to the [National Child Cancer Network Guideline Immunisation of children during and after cancer therapy](#).

Vaccine	Additional notes	Recommended schedule	Eligibility
<b>From 6 months post-HSCT</b>			
<b>Influenza</b>	<ul style="list-style-type: none"> <li>Annually, during the Influenza Immunisation Programme</li> </ul>	<ul style="list-style-type: none"> <li>Administer two doses four weeks apart in the first year post-HSCT, only the first dose is funded</li> <li>In subsequent years only one dose is required annually</li> </ul>	FUNDED
<b>SARS-CoV-2 (COVID-19)</b>	<ul style="list-style-type: none"> <li>Revaccination following immunosuppression                             <ul style="list-style-type: none"> <li>During outbreak, revaccination can begin from 3 months post-HSCT†</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Administer vaccine doses following the recommended three dose primary course</li> <li>Booster as age appropriate (mRNA-CV preferred)</li> </ul>	FUNDED
<b>From 12 months post-HSCT</b>			
<b>Tetanus/diphtheria/pertussis Tdap (Boostrix)</b>	<ul style="list-style-type: none"> <li>Revaccination following immunosuppression</li> </ul>	<ul style="list-style-type: none"> <li>Administer three doses at 0, 1, and 6 months</li> </ul>	FUNDED
<b>Polio IPV (Ipol)</b>	<ul style="list-style-type: none"> <li>Revaccination following immunosuppression</li> </ul>	<ul style="list-style-type: none"> <li>Administer three doses at 0, 1, and 6 months</li> </ul>	FUNDED
<b>Haemophilus influenzae type b Hib (Hiberix)</b>	<ul style="list-style-type: none"> <li>Revaccination following immunosuppression</li> <li>Three doses are recommended but:                             <ul style="list-style-type: none"> <li>One dose is funded</li> <li>Two doses are not funded                                     <ul style="list-style-type: none"> <li>No Hib vaccines are available for purchase through Healthcare Logistics</li> <li>ProPharma supplied Hiberix must be used for doses two and three</li> <li>No Immunisation Benefit Subsidy can be claimed</li> <li>The practice may wish to charge a vaccine administration fee</li> </ul> </li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Administer three doses at 0, 1, and 6 months</li> </ul>	FUNDED <i>One dose</i>
			NOT funded <i>Two further doses</i>
<b>Hepatitis B (Engerix-B)</b>	<ul style="list-style-type: none"> <li>Revaccination following immunosuppression</li> </ul>	<ul style="list-style-type: none"> <li>Administer three doses at 0, 1, and 6 months</li> </ul>	FUNDED
<b>HPV (Gardasil 9)</b>	<ul style="list-style-type: none"> <li>Males and females under 45 years of age</li> </ul>	<ul style="list-style-type: none"> <li>Administer three doses at 0, 2, and 6 months</li> </ul>	FUNDED <i>up to 27 years of age</i>
<b>Meningococcal B 4CMenB (Bexsero)</b>	<ul style="list-style-type: none"> <li>Can be co-administered with any other vaccine</li> </ul>	<ul style="list-style-type: none"> <li>Administer two doses 8 weeks apart</li> <li>Schedule a precall for a booster dose every 5 years</li> </ul>	FUNDED

## Foot notes

† or earlier, on advice from the treating specialist

# Immunisation for adults post-haematopoietic stem cell transplantation(HSCT)

Vaccine	Additional notes	Recommended schedule	Eligibility
<b>Meningococcal</b> MCV4-D (Menactra)	<ul style="list-style-type: none"> <li>No Neisvac-C (MenCCV) required</li> <li>A minimum of 4 weeks is required between administration of Prevenar13 and Menactra</li> </ul>	<ul style="list-style-type: none"> <li>Administer two doses 8 weeks apart</li> </ul>	FUNDED
<b>Pneumococcal</b> PCV13 (Prevenar 13)	<ul style="list-style-type: none"> <li>Minimum of 4 weeks is required between administration of Prevenar 13 and Menactra</li> <li>If Pneumovax23 has been administered before Prevenar13, wait one year to give Prevenar13</li> </ul>	<ul style="list-style-type: none"> <li>Administer one dose</li> </ul>	FUNDED
<b>Pneumococcal</b> 23PPV (Pneumovax 23)	<ul style="list-style-type: none"> <li>Administer Pneumovax 23 a minimum of 8 weeks after Prevenar 13</li> </ul>	<p><b>If aged 18 years to under 60 years</b></p> <ul style="list-style-type: none"> <li>Administer one dose</li> <li>Schedule a precall for the second dose in 5 years</li> <li>Schedule a precall for the third/final dose 5 years after second dose or at age 65 years, whichever is later</li> </ul> <p><b>If aged 60 years or older</b></p> <ul style="list-style-type: none"> <li>Administer one dose</li> <li>Schedule a precall for the second/final dose in 5 years</li> </ul>	FUNDED
<b>From 24 months post-HSCT</b>			
<b>Measles/mumps/rubella</b> MMR (Priorix)	<ul style="list-style-type: none"> <li>(Re)vaccination following immunosuppression</li> </ul>	<p><b>If immunocompetent</b></p> <ul style="list-style-type: none"> <li>Administer two doses at least 4 weeks apart a,b,c,d</li> </ul>	<p>FUNDED for immunocompetent individuals who meet the eligibility criteria</p> <p>CONTRAINDICATED for individuals with extensive graft vs. host disease or on significantly immunosuppressive medication<sup>a</sup></p>
<b>Varicella (chickenpox)</b> VV (Varivax)	<ul style="list-style-type: none"> <li>(Re)vaccination following immunosuppression</li> </ul>	<p><b>If immunocompetent</b></p> <ul style="list-style-type: none"> <li>Administer two doses at least 4 weeks apart a,b,c,d,e</li> </ul>	
<b>Herpes Zoster</b> Recombinant rZV (Shingrix)	<p>Recommended for:</p> <ul style="list-style-type: none"> <li>Adults from the age of 50 years and above</li> <li>Adults from the age of 18 years and above who are at increased risk of shingles</li> <li>Funded from age 65 years</li> </ul>	<ul style="list-style-type: none"> <li>Administer 2 doses at least 2–6 months apart</li> </ul>	<p>Recommended NOT FUNDED 50–64 years</p> <p>FUNDED Aged 65 years</p>

## Foot notes

- Not routinely recommended for individuals with extensive graft vs. host disease or on significantly immunosuppressive medication.
- Individuals who have received immunoglobulin or other blood products may require time for passive antibodies to decrease prior to administration of live varicella and MMR vaccines. Refer to Table A6.1 in the IHB
- Two or more live vaccines can be given at the same visit. However, when live vaccines are administered at different visits, a minimum interval of 4 weeks is required.
- Consider normal immunoglobulin or zoster immunoglobulin for post-exposure measles or varicella prophylaxis respectively in non-immune individuals.
- Two doses of varicella vaccines are funded for a household contact of an individual who is severely immunocompromised or undergoing a procedure leading to immunocompromise, where the household contact has no clinical history of varicella infection or immunisation.